



Inflammasome and Cross-Talk with DNA Sensing Pathway in Severe Asthma

Bernhard Ryffel*

Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), University of Orleans, France

Short Communication

Allergic asthma has increased dramatically in prevalence and severity over the last decades. Both clinical and experimental data support an important role of Th2 immune cells in the allergic response [1]. We reported that the NLRP3 expressed on T cells may function as transcriptional regulator of Th2 differentiation [2]. Innate cells producing rapidly large amounts of type 2 cytokines sparked the interest in type 2 Innate Lymphoid Cells (ILC), which have diverse biological processes including allergic responses [3]. The contribution of myeloid cells and crucial role of epithelial cells activated by allergen is now well established in asthma [4].

Several recent investigations revealed that airway exposure to allergen in sensitized individuals causes the release of danger signals including ATP [5], uric acid and other crystals [6] activating the NLRP3 inflammasome complex [7,8]. NLRP3 triggers the caspase-1 cleaving pro-IL-1 β to mature IL-1 β , highly inflammatory cytokine [9,10]. The production of pro-IL-1 β requires Toll-Like Receptor (TLR) signal which is provided by endotoxin or other agonists [11]. IL-1 β creates a pro-inflammatory milieu with the production of IL-6, IL-23 and chemokines which mobilize neutrophils and enhance Th17 cell differentiation in the lung which is mocked by neutralizing IL-17

OPEN ACCESS

*Correspondence:

Bernhard Ryffel, Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS, University of Orleans, F-45071, Orleans, France, Tel: 0033 238 25 54 39; 0033 6 29 15 22 87;

E-mail: bryffel@cnrs-orleans.fr

Received Date: 13 Oct 2021

Accepted Date: 15 Nov 2021

Published Date: 25 Nov 2021


Citation:

Ryffel B. Inflammasome and Cross-Talk with DNA Sensing Pathway in Severe Asthma. *J Respir Med Lung Dis.* 2021; 6(1): 1059.

ISSN: 2475-5761

Copyright © 2021 Bernhard Ryffel.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



antibody [12]. The cellular and molecular events of NLRP3 activation resulting in IL-1 and IL-18 dependent inflammation are depicted in Figure 1. Alternative pathways may also be of interest such cell stress and death induced free DNA activating the DNA sensing cGAS and STING pathway triggering type I interferon dependent inflammation [13]. A cross-talk of the NLRP3 and cGAS and STING pathways is also considered.

Severe asthma is a broad term of treatment resistant asthma Th2 dependent immune response with airways hyper reactivity and eosinophils, or Th17 response with neutrophils and is major therapeutic challenge [14]. Severe asthma is associated increased IL-1R family transcript in the sputum [15]. We used repeated house dust mite and birch pollen induced mouse models which mimic severe allergic asthma [16,17], and other experimental mouse models as reviewed [18]. An important feature of severe asthma is reactivation by environmental factors such as airway pollution including ozone [19,20]. Ozone causes airways hyper reactivity [21], and disruption of the respiratory barrier with neutrophilic inflammation, emphysema and fibrosis [22,23]. Bacterial infection with *S. pneumonia* [24] and viral infection by rhinovirus, RSV and other viruses may aggravate allergic asthma [25]. In models of papain and alternaria proteases induced allergic inflammation we demonstrated a critical role of type 2 and 3 ILCs expressing acetylcholine, which is abrogated in cell specific deficient mice [26,27].

Therapeutic Targeting of NLRP3 Inflammasome

There is ample evidence that the NLRP3 inflammasome is activated and required to develop allergic airway inflammation and that IL-17 contributes to severe, neutrophilic asthma, which is glucocorticoid resistant [28,29]. Pharmacological inhibition of NLRP3 by the small molecules such as MCC950 related compounds may be an attractive choice to inhibit severe asthma [14,30].

Therefore, targeting the NLRP3 inflammasome complex is of tremendous therapeutic interest to inhibit severe asthma, but needs further clinical confirmation. Cell death occurring upon allergen exposure liberates extracellular or cytosolic DNA, which is highly inflammatory strongly, suggests that chemical blockade of the DNA sensing cGAS and STING pathway is a novel alternative to attenuate severe allergic asthma, which is under investigation in our laboratory [13].

References

- Putt F, Denney L, Gregory LG, Vuononvirta J, Oliver R, Entwistle LJ, et al. Pulmonary environmental cues drive group 2 innate lymphoid cell dynamics in mice and humans. *Sci Immunol*. 2019;4(36):eaav7638.
- Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. *Nat Immunol*. 2015;16(8):859-70.
- Lloyd CM, Snelgrove RJ. Type 2 immunity: Expanding our view. *Sci Immunol*. 2018;3(25):eaat1604.
- Hewitt RJ, Lloyd CM. Regulation of immune responses by the airway epithelial cell landscape. *Nat Rev Immunol*. 2021;21:347-62.
- Riteau N, Baron L, Villeret B, Guillou N, Savigny F, Ryffel B, et al. ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation. *Cell Death Dis*. 2012;3(10):e403.
- Gasse P, Riteau N, Charron S, Girre S, Fick L, Pétrilli V, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. *Am J Respir Crit Care Med*. 2009;179(10):903-13.
- Besnard AG, Togbe D, Couillin I, Tan Z, Zheng SG, Erard F, et al. Inflammasome-IL-1-Th17 response in allergic lung inflammation. *J Mol Cell Biol*. 2012;4(1):3-10.
- Pinkerton JW, Kim RY, Robertson AAB, Hirota JA, Wood LG, Knight DA, et al. Inflammasomes in the lung. *Mol Immunol*. 2017;86:44-55.
- Dinarello CA. Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity. *Immunol Rev*. 2018;281(1):5-7.
- Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. *Immunity*. 2019;50(4):778-95.
- Gombault A, Baron L, Couillin I. ATP release and purinergic signaling in NLRP3 inflammasome activation. *Front Immunol*. 2013;3:414.
- Chenuet P, Fauconnier L, Madouri F, Marchiol T, Rouxel N, Ledru A, et al. Neutralization of either IL-17A or IL-17F is sufficient to inhibit house dust mite induced allergic asthma in mice. *Clin Sci (Lond)*. 2017;131(20):2533-48.
- Benmerzoug S, Ryffel B, Togbe D, Quesniaux VFJ. Self-DNA sensing in lung inflammatory diseases. *Trends Immunol*. 2019;40(8):719-34.
- Theofani E, Semitekolou M, Morianos I, Samitas K, Xanthou G. Targeting NLRP3 inflammasome activation in severe asthma. *J Clin Med*. 2019;8(10):1615.
- Rossios C, Pavlidis S, Hoda U, Kuo CH, Wiegman C, Russell K, et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. *J Allergy Clin Immunol*. 2018;141(2):560-70.
- Madouri F, Chenuet P, Beuraud C, Fauconnier L, Marchiol T, Rouxel N, et al. Protein kinase C θ controls type 2 innate lymphoid cell and TH2 responses to house dust mite allergen. *J Allergy Clin Immunol*. 2017;139(5):1650-66.
- Madouri F, Guillou N, Fauconnier L, Marchiol T, Rouxel N, Chenuet P, et al. Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. *J Mol Cell Biol*. 2015;7(4):351-65.
- Branchett WJ, Walker SA, Lloyd CM. Experimental mouse models of asthma and analysis of CD4 T cells. *Methods Mol Biol*. 2021;2285:329-48.
- Chung KF, Togbe D, Ryffel B. Editorial: Ozone as a driver of lung inflammation and innate immunity and as a model for lung disease. *Front Immunol*. 2021;12:714161.
- Michaudel C, Couturier-Maillard A, Chenuet P, Maillet I, Mura C, Couillin I, et al. Inflammasome, IL-1 and inflammation in ozone-induced lung injury. *Am J Clin Exp Immunol*. 2016;5(1):33-40.
- Pichavant M, Goya S, Meyer EH, Johnston RA, Kim HY, Matangkasombut P, et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. *J Exp Med*. 2008;205(2):385-93.
- Michaudel C, Mackowiak C, Maillet I, Fauconnier L, Akdis CA, Sokolowska M, et al. Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL-33. *J Allergy Clin Immunol*. 2018;142(3):942-58.
- Sokolowska M, Quesniaux VFJ, Akdis CA, Chung KF, Ryffel B, Togbe D. Acute respiratory barrier disruption by ozone exposure in mice. *Front Immunol*. 2019;10:2169.
- Hassane M, Demon D, Soulard D, Fontaine J, Keller LE, Patin EC, et al. Neutrophilic NLRP3 inflammasome-dependent IL-1 β secretion regulates the $\gamma\delta$ T17 cell response in respiratory bacterial infections. *Mucosal Immunol*. 2017;10(4):1056-68.

25. Rajput C, Han M, Ishikawa T, Lei J, Goldsmith AM, Jazaeri S, et al. Rhinovirus C infection induces type 2 innate lymphoid cell expansion and eosinophilic airway inflammation. *Front Immunol*. 2021;12:649520.
26. Darby M, Roberts LB, Mackowiak C, Chetty A, Tinelli S, Schnoeller C, et al. ILC3-derived acetylcholine promotes protease-driven allergic lung pathology. *J Allergy Clin Immunol*. 2021;147(4):1513-6.e4.
27. Roberts LB, Schnoeller C, Berkachy R, Darby M, Pillaye J, Oudhoff MJ, et al. Acetylcholine production by group 2 innate lymphoid cells promotes mucosal immunity to helminths. *Sci Immunol*. 2021;6(57):eabd0359.
28. Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, et al. Role for NLRP3 inflammasome-mediated, IL-1beta-dependent responses in severe, steroid-resistant asthma. *Am J Respir Crit Care Med*. 2017;196(3):283-97.
29. Wadhwa R, Dua K, Adcock IM, Horvat JC, Kim RY, Hansbro PM. Cellular mechanisms underlying steroid-resistant asthma. *Eur Respir Rev*. 2019;28(153):190096.
30. Corcoran SE, Halai R, Cooper MA. Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950. *Pharmacol Rev*. 2021;73(3):968-1000.